Business
NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Leveraging Combination Studies, Immune Checkpoint Inhibitors for Potent Anti-Cancer Response
New York, New York--(Newsfile Corp. - October 4, 2018) - NetworkNewsAudio announces the Audi...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"NetworkNewsAudio Announces Audio Press Release (APR) on BriaCell Therapeutics Corp. Leveraging Combination Studies, Immune Checkpoint Inhibitors for Potent Anti-Cancer ResponseNew York, New York--(Newsfile Corp. - October 4, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled \"Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment,\" featuring BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSXV: BCT).To hear the NetworkNewsAudio version, visit: http://nnw.fm/0UHqYTo read the full editorial, visit: http://nnw.fm/Ixnq5It is important to note that immune checkpoint inhibitors such as pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) have come to the forefront in the fight against cancer with substantial benefits for some patients. The significance of immune checkpoints has been recognized by the Nobel committee by awarding Drs. Honjo (PD-1) and Allison (CTLA-4) with the 2018 Nobel Prize in Physiology or Medicine. This is highly encouraging for BriaCell because the company is using these check point inhibitors in combination with Bria-IMT in its ongoing Phase IIa studies in advanced breast cancer patients.\"We believe that combination studies with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with Keytruda or Yervoy,\" Williams stated in the press release announcing the results. \"In our view, the combination of Bria-IMT with Keytruda or Yervoy has the potential to provide a new therapeutic option and substantial clinical benefit in heavily pre-treated advanced breast cancer patients where there remains a significant unmet need.\"About BriaCellBriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body's own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. For more information, visit the company's website at www.briacell.com.About NetworkNewsAudioNetworkNewsAudio (NNA) , a Net...